GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Candel Therapeutics Inc (NAS:CADL) » Definitions » Property, Plant and Equipment

Candel Therapeutics (Candel Therapeutics) Property, Plant and Equipment : $3.71 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Candel Therapeutics Property, Plant and Equipment?

Candel Therapeutics's quarterly net PPE declined from Sep. 2023 ($4.56 Mil) to Dec. 2023 ($4.02 Mil) and declined from Dec. 2023 ($4.02 Mil) to Mar. 2024 ($3.71 Mil).

Candel Therapeutics's annual net PPE increased from Dec. 2021 ($3.84 Mil) to Dec. 2022 ($5.48 Mil) but then declined from Dec. 2022 ($5.48 Mil) to Dec. 2023 ($4.02 Mil).


Candel Therapeutics Property, Plant and Equipment Historical Data

The historical data trend for Candel Therapeutics's Property, Plant and Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Candel Therapeutics Property, Plant and Equipment Chart

Candel Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Property, Plant and Equipment
0.43 2.79 3.84 5.48 4.02

Candel Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Property, Plant and Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.10 4.92 4.56 4.02 3.71

Candel Therapeutics Property, Plant and Equipment Calculation

Property, Plant and Equipment (PPE) are the fixed assets of the companyFixed assets are also known as non-current assets.

Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.

Some of the most common parts of property, plant, and equipment are:


Land
Buildings (and leasehold improvements)
Transportation equipment
Manufacturing equipment
Office equipment
Office furniture

Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:


Track
Ties
Ballast
Bridges
Tunnels
Signals
Locomotives
Freight Cars

There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.

The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.

For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.

All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.

The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.


Candel Therapeutics  (NAS:CADL) Property, Plant and Equipment Explanation

A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.

Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.

Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.


Candel Therapeutics Property, Plant and Equipment Related Terms

Thank you for viewing the detailed overview of Candel Therapeutics's Property, Plant and Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.


Candel Therapeutics (Candel Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
117 Kendrick Street, Suite 450, Needham, MA, USA, 02494
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Executives
Nicoletta Loggia director CANDEL THERAPEUTICS, INC., 117 KENDRICK ST., SUITE 450, NEEDHAM MA 02494
Jason Amello officer: Chief Financial Officer 500 KENDALL STREET, CAMBRIDGE MA 01824
Paul Peter Tak director, officer: President & CEO CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Christopher Martell director CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Seshu Tyagarajan officer: See Remarks CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Joseph C Papa director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Francesca Barone officer: Chief Scientific Officer CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
William Garrett Nichols officer: Chief Medical Officer C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Gary J. Nabel director C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Renee Gaeta director C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Paul B Manning director 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Diem Nguyen director C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Nathan Caffo officer: Chief Business Officer C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
John J Canepa officer: Chief Financial Officer 241 MATTINSON DRIVE, CONCORD MA 01742
Susan B. Stewart officer: Chief Regulatory Officer C/O TOKAI PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142

Candel Therapeutics (Candel Therapeutics) Headlines

From GuruFocus

Candel Therapeutics to Participate in Upcoming B. Riley Oncology Conference

By Stock market mentor Stock market mentor 01-12-2023

Candel Therapeutics to Host Virtual R&D Day on December 6, 2022

By Value_Insider Value_Insider 11-29-2022

Candel Therapeutics to Participate in Guggenheim Healthcare Talks 2023 Oncology Day

By Stock market mentor Stock market mentor 02-01-2023